Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > J Korean Cancer Assoc > Volume 22(3); 1990 > Article
Original Article
Cyclophosphamide , Adriamycin and Cisplatin ( CAP ) Combination Chemotherapy for Invasive Thymoma
Young Suk Park, Young Hyuk Im, Won Ki Kang, Chang In Suh, Kee Hyung Lee, Kyung Hae Jung, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
Journal of the Korean Cancer Association 1990;22(3): 532-539.
  • 3,409 Views
  • 39 Download
  • 0 Crossref
  • 0 Scopus
prev next

Between October 1985 and January 1990, the combination chemotherapy with cyclophosphamide, adriamycin and cisplatin (CAP) has been administered in 16 patients with invasive, recurrent or metastatic thymoma. Among 14 evaluable patients, 1 patient(7%) achieved a complete response and 4 patients (29%) had a partial response. The 4 year overall survival rates were 56.7% with a median follow-up of 11.5 months. The mast frequent hematologic toxicity was leukopenia (15.9%) and nonhematologic toxicity (WHO criteria; grade II) were alopecia (80%) and nausea/vomiting (66.7%). The CAP regimen is effective and well tolerated for the treatment of invasive thymoma, and further study is needed to confirm the relative effectiveness of CAP regimen in comparison with other regimens and to find out the prognostic factors related to response rate and survival

  • Cite
    CITE
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Cyclophosphamide , Adriamycin and Cisplatin ( CAP ) Combination Chemotherapy for Invasive Thymoma
    J Korean Cancer Assoc. 1990;22(3):532-539.
    Close

Cancer Res Treat : Journal of the Korean Cancer Association
Close layer
TOP